In addition, a post-hoc analysis of the CIGMA trial demonstrated a significant relative reduction in all-cause mortality of 54–68% using IgM- and IgA enriched immunoglobulins in patients with severe pneumonia and had high C-reactive protein (CRP), low IgM and high CRP/low IgM ratios at baseline compared to placebo [72]. This evidence concerns the gene CD40LG and pneumonia.